Table 2 Time lapse between VL and PKDL with respect to the drug used for VL treatment
Anti-leishmanial drug | No. (%) patients | Median time lapse after VL treatment (months) | Range (months) |
|---|---|---|---|
SAG | 210 (93.33) | 36 | 1–384 |
Amphotericin B | 12 (5.33) | 48 | 3.6–84 |
Miltefosine | 3 (1.33) | 21 | 12–36 |